Importance Glioblastomas and malignant gliomas are the most common primary malignant
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …

Many patients with malignant gliomas do not respond to alkylating agent chemotherapy.
Alkylator resistance of glioma cells is mainly mediated by the DNA repair enzyme O 6 …

Although machine learning (ML) has shown promise across disciplines, out-of-sample
generalizability is concerning. This is currently addressed by sharing multi-site data, but …

This guideline provides recommendations for diagnostic and therapeutic procedures for
patients with malignant gliomas. We differentiate evidence-based standards from …

Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and
chemotherapy, generally with temozolomide. However, disease recurs in almost all patients …

Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …

Integration of external control data, with patient-level information, in clinical trials has the
potential to accelerate the development of new treatments in neuro-oncology by …

Antiangiogenic therapy has shown clear activity and improved survival benefit for certain
tumor types. However, an incomplete understanding of the mechanisms of action of …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Purpose: Antiangiogenic therapy is effective in blocking vascular permeability, inhibiting
vascular proliferation, and slowing tumor growth, but studies in multiple cancer types have …